checkAd

     146  0 Kommentare GBT is Working on its qTerm Device Improvements as a Preparation for its FDA Certification Process - Seite 2

    "We believe these changes will significantly increase the device’s performance, accuracy, and consistency we are required to meet during the FDA certification. We believe these changes will ensure the product's safety, accuracy, and reliability along with high quality and efficiency. This technology, assuming we receive FDA certification of which there is no guarantee, is planned to be marketed and sold for personal and clinics usage also targeting it for the telemedicine arena. Another aspect is the device’s planned Artificial Intelligence technology that will be offering advanced features like real-time health statistics, analytics, monitoring and real time, geographically proximity alert to assist with avoiding health risks. The modifications also are focus on human engineering aspect in order to ensure easier usability for the vitals measurements like finger’s position pointers and physical finger’s location structural design. We put extra emphasis on making the device easy for use, mainly intuitive. Vitals results can be crucial indicators to assist with early detection of illness and we are working to improve the device’s performance and capabilities as preparations efforts for FDA clearance. It is in our R&D culture to constantly improve our technology in efforts to bring it to the highest standards and regulations, particularly in the medicine domain when it can save lives." Said Danny Rittman GBT/Tokenize and the Company’s CTO.

    About Us

    GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

    Seite 2 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    GBT is Working on its qTerm Device Improvements as a Preparation for its FDA Certification Process - Seite 2 SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) - GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”) via GBT Tokenize Corp (“GBT/Tokenize”) , has started a series of improvements for its qTerm device as preparations for FDA certification …